Neovasc

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neovasc Inc. is a specialty medical device company that develops and manufactures products for the rapidly growing cardiovascular device marketplace.Neovasc Inc. offers pericardial tissue processing, vascular product development, design, and manufacturing solutions to industry partners.

Neovasc Inc (NASDAQ: NVCN) has announced the publication of an article highlighting the long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer system in the International Journal of Cardiology. The study dubbed RESOURCE is an observational, retrospective registry that includes 658 patients in Europe, the U.K., and Israel.

Real World Study Shows Neovasc's Reducer Is Safe, Efficacious In Patients With Refractory Angina

VANCOUVER and MINNEAPOLIS, June 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology.

Largest Real-World Registry Supporting Neovasc Reducer™ Safety and Efficacy Outcomes Published in International Journal of Cardiology

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 18, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study" in the International Journal of Cardiology.The article, authored by Francesco Ponticelli, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer™ ("Reducer")...

Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology

VANCOUVER and MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company's core business activities.

Neovasc Provides Corporate Update

Neovasc Reducer System Receives First National Reimbursement in Europe

Vancouver, BC, Canada, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the “Meeting”).

Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

VANCOUVER and MINNEAPOLIS, May 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from April 12, 2021 to May 21, 2021, the Company no longer meets the minimum bid price requirement.

Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

VANCOUVER and MINNEAPOLIS, May 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the court had found that Edwards Lifesciences LLC ("Edwards") had contributed in part to the invention of the Tiara™ and awarded to Edwards co-entitlement rights to the disputed Tiara™ European patent application. There are no monetary awards associated with these matters and no damages award was recognized.

Neovasc Provides Update on German Litigation

VANCOUVER and MINNEAPOLIS, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire   -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into current cardiovascular and microvascular disease treatments. The symposium titled, “Latest clinical evidence and practical aspects to start Reducer therapy in your center,” will be presented at the 2021 EuroPCR, taking place digitally from May 18-20, 2021. EuroPCR is a leading opportunity for cardiologists to exchange ideas and latest best practices.

Neovasc to Sponsor Symposium on Reducer at EuroPCR

VANCOUVER and MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society (“CCS”) Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany.

Neovasc Announces First Patient Enrollment in COSIMA Trial

Neovasc's (NVCN) CEO Fred Colen on Q1 2021 Results - Earnings Call Transcript

Neovasc (NVCN) delivered earnings and revenue surprises of 60.00% and -24.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q1 Loss, Lags Revenue Estimates

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 6, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the first quarter ended March 31, 2021.First Quarter HighlightsGenerated revenue of $451,794 in the quarter as Neovasc Reducer™ implants rebounded after being suppressed for much of 2020 due to the COVID-19 pandemic. Continued to advance our program to expand reimbursement for Reducer in the EU and the US, and...

Neovasc Announces First Quarter 2021 Financial Results

Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Neovasc (NVCN) Report Negative Earnings Next Week? What You Should Know

VANCOUVER and MINNEAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ (“Reducer”).

Neovasc Provides Reducer Reimbursement Progress Update

VANCOUVER and MINNEAPOLIS, April 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.  Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.

Neovasc to Report First Quarter 2021 Financial Results on May 6, 2021

VANCOUVER and MINNEAPOLIS, April 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.”

Neovasc Comments on EuroIntervention Article

VANCOUVER and MINNEAPOLIS, April 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is collaborating with its European Notified Body (the “Notified Body”) on potential next steps.

Neovasc Provides Tiara TA Update

Neovasc, Inc. (NVCN) CEO Fred Colen on Q4 2020 Results - Earnings Call Transcript

Neovasc (NVCN) delivered earnings and revenue surprises of 66.67% and -6.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Neovasc (NVCN) Reports Q4 Loss, Misses Revenue Estimates

VANCOUVER and MINNEAPOLIS, March 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.

Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results

VANCOUVER and MINNEAPOLIS, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021.  Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.

Neovasc to Report Fourth Quarter and Fiscal Year 2020 Results on March 11, 2021

VANCOUVER and MINNEAPOLIS, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021.  A recorded presentation by Bill Little, Neovasc's Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9.  Company management will also be scheduling one-on-one meetings with investors; meetings may be requested through H.C. Wainwright.

Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference

VANCOUVER and MINNEAPOLIS, March 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study.”

Neovasc Comments on Clinical Cardiology Journal Publication

VANCOUVER and MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") ( NASDAQ , TSX : NVCN), has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the “Listing Rules”).

News for Neovasc Stock (NVCN)